AbbVie Inc. EV/EBITDA

EV/EBITDA of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including EV/EBITDA growth rates and interactive chart. EV/EBITDA is a ratio that compares a company’s Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation & Amortization (EBITDA). The EV/EBITDA ratio is a valuation metric used to compare the relative value of different businesses. A low EV/EBITDA compared to a stock’s historical average or industry can indicate undervaluation.

Highlights and Quick Summary

Current EV/EBITDA of AbbVie Inc. is 18.61 (as of December 30, 2019)
  • EV/EBITDA for the quarter ending December 30, 2019 was 18.61 (a 13.57% increase compared to previous quarter)
  • Year-over-year quarterly EV/EBITDA increased by 2.15%
  • Annual EV/EBITDA for 2019 was 18.61 (a -13.0% decrease from previous year)
  • Annual EV/EBITDA for 2018 was 21.39 (a 27.98% increase from previous year)
  • Annual EV/EBITDA for 2017 was 16.72 (a 33.69% increase from previous year)
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EV/EBITDA of AbbVie Inc.

Most recent EV/EBITDAof ABBV including historical data for past 10 years.

Interactive Chart of EV/EBITDA of AbbVie Inc.

AbbVie Inc. EV/EBITDA for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 18.61 16.39 15.59 18.22 18.61
2018 21.39 14.25 15.23 14.93 21.39
2017 16.72 14.96 13.09 12.52 16.72
2016 12.5 12.89 13.43 12.74 12.5
2015 14.28 19.52 27.34 22.42 14.28
2014 26.44 15.7 14.3 13.27 26.44
2013 13.53 10.97 10.05 10.12 13.53
2012 9.05 9.05 9.05 9.05 9.05
2011 9.05 9.05 9.05 9.05 9.05
2010 – – – – 9.05
2009 – – – – 9.05

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
© stockrow.com